Handbook of Clinical medicine

by 250mg/12h every 2wks up to max 1 . 5g/12h (if eGFR >80). SE: psychiatric side-eff ects are common, eg depression, agi- tation. Other SES: D&V, dyspepsia, drowsiness, diplopia, blood dyscrasias. Sodium valproate: Initially 300mg/12h, increase by 100mg/12h every 3d up to max 30mg/kg (or 2 . 5g) daily. SE: teratogenic. Nausea is very common (take with food). Other SES: liver failure (watch LFT especially during 1st 6 months), pancreatitis, hair loss (grows back curly), oedema, ataxia, tremor, thrombocytopenia, encephalopa- thy (hyperammonaemia). Phenytoin: No longer 1st line due to toxicity (nystagmus, diplopia, tremor, dys- arthria, ataxia) and SE: intellect, depression, coarse facial features, acne, gum hyper trophy, polyneuropathy, blood dyscra sias. Blood levels required for dosage. Carbamazepine, phenytoin, and barbiturates are liver enzyme inducing. Epilepsy and pregnancy Epilepsy carries a 5% risk of fetal abnormalities, so good seizure control prior to conception and during pregnancy is vital. Yet some anti-epileptics are teratogenic: the patient must be given accurate information and counselling about contracep- tion, conception, pregnancy, and breastfeeding in order to make informed deci- sions. In particular: • Advise women of child-bearing age to take folic acid 5mg/d. • Strictly avoid sodium valproate and polytherapy prior to conception and during
